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Chapter 1 – INTRODUCTION: 
1.1 The Autoinflammatory Diseases 
The autoinflammatory diseases (AIDs) are a group of inflammatory 
conditions related to abnormal regulation of innate immunity1, caused by 
mutations of genes coding for proteins that play a pivotal role in the regulation 
of the inflammatory response. The first gene identified was the MEFV gene in 
1997.The spectrum of autoinflammatory disorders ranges from monogenic 
diseases such as FMF to multifactorial diseases like Behcet syndrome.2 Over the 
last decade, a number of monogenic and multifactorial diseases have been 
identified or reclassified as autoinflammatory in aetiology3. Due to their genetic 
nature, most of these disorders have an early onset, ranging from the first hours 
to the second decade of life. Only a limited number of patients experience a 
disease onset during adulthood4. Clinically the autoinflammatory syndromes are 
characterized by recurrent flares of systemic inflammation presenting in the 
majority of cases as sudden fever episodes associated with elevation of acute 
phase reactants together with a number of clinical manifestations such as rash, 
serositis (peritonitis, pleurisy), lymphadenopathy and arthritis. Symptom-free 
intervals are characterized by complete wellbeing, normal growth and complete 
normalization of acute phase reactants. Familial Mediterranean fever (FMF, 
MIM 249100), mevalonate-kinase deficiency (MKD, MIM 260920) and tumor 
necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS, MIM 
142680) are the three monogenic disorders subsumed under the term periodic 
fevers. A systemic inflammation dominated by a characteristic urticarial rash 
associated with a number of other clinical symptoms is typical of familial cold 
autoinflammatory syndrome (FCAS, MIM 120100), Muckle-Wells syndrome 
5 
 
(MWS, MIM 191900) and chronic infantile neurological cutaneous and articular 
syndrome (CINCA, MIM 607115). These diseases represent the clinical 
spectrum of different mutations of a gene named cold-induced autoinflammatory 
syndrome 1 (CIAS-1, or NLRP3) coding for a protein called cryopyrin. Hence 
these disorders are also known under the term cryopyrin-associated periodic 
syndromes (CAPS). Other conditions are characterized by the appearance of 
typical granulomatous formations (granulomatous disorders). Blau’s syndrome 
(MIM 186580), also known as familial juvenile systemic granulomatosis, 
presents with noncaseating granulomatous inflammation affecting the joint, skin, 
and uveal tract (the triad of arthritis, dermatitis and uveitis) and is associated 
with mutations of the NACHT domain of the gene CARD15 (or NOD2). Of note 
is that mutations in this same gene have been associated with Crohn’s disease, 
another granulomatous disease. Other rare disorders dominated by the presence 
of sterile pyogen abscesses chiefly affecting skin, joints and bones (pyogenic 
disorders) include the PAPA syndrome (pyogenic sterile arthritis, pyoderma 
gangrenosum and acne) (MIM 604416), associated with mutations of the CD2-
binding protein 1 (CD2BP1 or PSTPIP1) gene, the Majeed syndrome (MIM 
609628), characterized by chronic recurrent multifocal osteomyelitis, congenital 
dyserythropoietic anaemia and neutrophilic dermatosis, caused by mutations of 
LPIN2 gene, and deficiency of the interleukin-1receptor antagonist (DIRA) 
(MIM 612852), a recently identified autosomal recessive autoinflammatory 
syndrome characterized by severe systemic inflammation beginning 
approximately at the time of birth with multifocal osteomyelitis, periostitis and 
pustulosis and caused by mutations of the IL1RN gene encoding interleukin-1 
receptor antagonist. Even if nowadays there is much more awareness of these 
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disorders, the extreme rarity and relatively recent identification as autonomous 





Gene Main clinical 
features 
Periodic Fever Familial 
Mediterranean Fever  
MEFV Short duration of fever 
episodes: 24–48 hours. 
Abdominal and chest 
pain. Erysipelas-like 
erythema.  Renal 
amyloidosis in untreated 
patients. Good response 
to colchicine. Possible 




MVK Early onset Mean 
duration of fever 
episodes: 4–5 days. Poor 
conditions during fever 
episodes. Abdominal 
pain, vomiting and 
diarrhea. Splenomegaly. 
Good response to 






TNFRSFS1A Prolonged fever 
episodes: 1–3 weeks. 
Periorbital edema, 
monocytic fasciitis. 
Incidence of renal 
amyloidosis: 15‒25%. 














articular syndrome  
NLRP3 FCAS: rash, fever and 
arthralgia after cold 
exposure.  







aseptic meningitis and 
bone deformities. Good 
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response to IL-1 
blockade. 
FCAS2 NLRP12 Periodic fever after cold 
exposure, hearing loss. 
NLRC4-associated 
disease  





Blau’s syndrome  CARD15 Early onset. Polyarticular 
granulomatous arthritis, 
uveitis, skin rash. Good 





PAPA syndrome  PSTPIP1 Pyogenic sterile arthritis, 
pyogenic gangrenosum, 
cystic acne. Good 
response to IL-1 
blockade 
COPA  COPalfa Early polyarthritis, lung 
involvement 









response to anakinra 
DITRA  IL36RN Generalized 
pustular psoriasis, 
recurrent fever 

























ORAS  FAM105B Neonatal onset of fever, 
diarrhea, panniculitis 
Vasculopathy 
and ulcers  
SAVI   TMEM173 Early vasculopathy 


























virus and bacteria  
PLAID/APLAID  PLCgamma2 Skin lesions, cellulitis, 
interstitial lung disease, 
athralgia, uveitis, bowel 
inflammatory disease, 
variable deficit of B cells 
Multifactorial 
diseases 
CNO -  Recurrent steril 
osteomyelitis 
Behcet syndrome -  Recurrent oral-
genital ulcers 
PFAPA syndrome -  Periodic fever, aphthous 
stomatitis, adenitis 
 Table 1: Classification of Autoinflammatory Diseases (from Federici et al, 
2012) 
Chapter 2 - AIM OF THE STUDY: 
The aim of the present study is to perform a descriptive evaluation of 
demographic features (geographic distribution, diagnostic delay, genetic 
analysis), clinical manifestation, response to treatment and safety of AIDs using 
data extrapolated from the International Eurofever Registry. Further aim is to 
focus on genetic analysis, with particular interest about pathogenic/non 
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pathogenic variants and to analyze the most used therapeutic strategy in different 
countries, with particular attention for biologic drugs. Finally, after ten years 
from its creation, to examine Eurofever impact on Scientific community. 
Chapter 3 – METHODS: 
The data analyzed in the study were extracted from the Eurofever registry, 
which is hosted in the PRINTO website. From February 2015 we started the 
longitudinal collection of follow-up data for the patients already included in the 
Registry with particular focus on treatment, modification of the clinical picture, 
onset of complication/adverse events. We have included in the present study all 
the patients enrolled in the registry with complete demographic data up to 28 
September 2018. 
3.1 The creation of Eurofever Registry 
In 2008, thanks to a grant from the European Agency for Health and 
Consumers, an international initiative related to the novel group of rare 
conditions included under the umbrella term of autoinflammatory diseases was 
started: the Eurofever project. One of the main goal of the project was to 
establish an international registry on these rare conditions. At variance with the 
previous international initiatives which aimed to collect data of patients affected 
only by a single condition (MKD registry, Eurotraps, PFAFA registry), the 
Eurofever registry was conceived as a single source of information for known 
and future autoinflammatory diseases. Indeed, the major advantage of a single 
registry for different conditions is related to the possibility to collect 
demographic, genetic and clinical information in a homogenous fashion 
facilitating the comparison among the various conditions. Thanks to 
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collaboration with the Paediatric Rheumatology International Trials 
Organization (PRINTO, http://www. printo.it), the Eurofever registry was able 
to reach a large number of pediatric rheumatology centers already involved in 
the management of pediatric rheumatic conditions. Moreover, adult centers and 
members of the International Society of Systemic Autoinflammatory Diseases 
(ISSAID) and the European League Against Rheumatism (EULAR) were also 
engaged in the project in order to collect data also on adult patients. Indeed, the 
Eurofever project survey involved all centers linked to PRINTO that currently 
includes more than 400 centers in 60 countries worldwide. Beside the registry, 
the Eurofever project was an opportunity to bring together centers that care for 
patients with autoinflammatory diseases, establishing a network able to foster 
research in the field, including the organization of clinical trials. In this line, the 
development of new classification criteria and of new outcome measures for the 
autoinflammatory diseases were among the main aims of the project. The 
registry has elected an International Steering Committee that coordinate the all 
the activities of the registry. 
3.2 How the Eurofever registry was developed 
The registry was created in 2008 with the active collaboration of experts 
involved in the management of autoinflammatory diseases.5 The experts were 
asked to identify all significant variables for each disorder. The forms for data 
collection were divided into two parts: demographic and clinical data. 
Demographic data included: subject ID (patients were identified by 
alphanumeric code), date of birth, sex, ethnicity, country of birth, onset age, date 
of first visit to the center, patient diagnosis and molecular analysis. Genetic 
testing was not mandatory, but if performed, details were requested. These 
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included the gene screened and whether the complete gene was sequenced or the 
most relevant exons or just the most relevant point mutations and the laboratory 
where the test was performed. Finally, information on consanguinity and any 
relevant family history was collected. Clinical data included: (i) signs and 
symptoms, (ii) laboratory examinations, (iii) imaging and other diagnostic 
procedures and (iv) response to treatment(s). Further revisions of the forms were 
subsequently evaluated by the experts and inclusion criteria for each disease 
were established with a final approval of the definitive version during a 
Consensus Meeting in March 2009. Continuous revisions of the form are 
performed to include newly described diseases with genetic information and 
associated clinical manifestations. Access to the database is available only for 
centers authorized by PRINTO, with a username and password on an https 
platform. For each disease one coordinator (Disease-PI) was chosen among the 
associated and collaborating partner on the basis of their expertise in the specific 
diseases or participation to other ongoing initiatives in connection with the 
Eurofever Project. Data on the single diseases are under the direct responsibility 
of the Disease-PIs and Eurofever’s Steering Committee. Disease-PI elaborates 
data coming from the Registry according to the aims for their specific disease 
and in agreement with the Eurofever Steering Committee. General 
epidemiological data coming from the Registry are under the responsibility of 
the Steering Committee. All participants to Eurofever can prose further studies 
on a specific diseases or on particular aspects involving different diseases. 
Criteria for the evaluation of a secondary studies are the following: i) scientific 
relevance; ii) clinical/scientific experience of the proposer in the field; iii) 
number of patients enrolled in the Eurofever registry for a given disease. Ethical 
committee approval for patient enrollment in the registry was obtained by 
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participating centers as required by local legal requirements.6 Informed consent 
was signed by parents or legal representatives or by the patient of adequate age. 
Enrollment started in November 2009. In its first version, Eurofever was 
established as a cross-sectional registry, collecting information of the patients 
from disease onset to disease diagnosis. Despite the high amount of clinical 
variables included, the registry was built to avoid the possibility of missing data, 
through the elaboration of web-based forms that do not allow the progression of 
data entry in case of missing data in the required field. Despite this careful 
approach, the main limitation of the first version of the registry was the 
retrospective collection of data, prompting to a possible inaccurate collection of 
all the clinical information pertinent to each patient. For this reason, in 2015, the 
registry was transformed into a longitudinal registry, collecting information on 
a yearly basis on the clinical evolution and the efficacy and safety of different 
treatments used in these rare conditions. In particular, the sections related to 
treatment that in the original cross-sectional version of the registry were rather 
concise, were completely revised in order to enable entry of more detailed 
information on efficacy and safety of all treatments used to treat the different 
autoinflammatory conditions. The creation of this large cohort of patients 
affected by autoinflammatory diseases with an extended follow-up will be the 
base for better knowledge of these disorders, with a focus on 
genotype/phenotype correlation and long-term efficacy and safety of different 
treatments. Moreover, since approximately 75–80% of patients with clinical 
features consistent with autoinflammatory diseases have no recognized 
mutations in any of the known genes,7, 8 a large cohort of patients with undefined 
periodic fevers will allow characterization of novel genes in this current 
challenging disease group. 
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3.3 The Eurofever Registry objectives 
1. General objectives  
The main objective of Eurofever is to create a permanent network for the 
study of AIDs. Particularly, the project purposes are: 
 To improve early diagnosis of autoinflammatory diseases; 
 To give adequate information to the family of patients affected 
 To improve knowledge about clinical presentation, response to 
treatment and complications of these rare diseases. 
 
2. Primary Endpoints of the Registry: 
1. To collect data about clinical presentation, response to treatment. 
2. To evaluate moderate/severe adverse events (SAE) or events of 
special interest (ESI). 
3. To evaluate clinical remission with or without therapy, defined as 
the absence of signs and symptoms, and to evaluate the improvement 
with AIDAI score (activity index of autoinflammatory diseases).  
 
3. Secondary Endpoints: 
1) To publish new classification criteria evidence based  
2) To promote guidelines for genetic analysis  
3) To create permanent network for future study 
4) To identify cluster of patients of informative families with the aim 
to detect new genes o epigenetic factors involved in these diseases. 
5) To evaluate: 
- Incidence of severe adverse events among patients treated 
with different drugs. 
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- Treatment adherence and reasons of interruption/change 
of therapy 
- Time of relapse during treatment or after drug stop. 
- Disease predictors. 
3.4 Sections of the Registry  
The last version of the Registry presents three main sections. 
Section 1. Demographic information, diagnosis, molecular analysis 
 Demographic data of the patients (sex, onset age, diagnosis age) 
 Type of disease and diagnosis data 
 Molecular analysis (analyzed gene, detected mutations) 
 
Section 2. Clinical Features 
 Pattern of frequency 
 Number episodes/year 
 Signs and symptoms related to the disease 
 Routine and specific blood examinations 
 Imaging and other diagnostic procedures 
 
Section 3. Longitudinal section of the study 
 Therapy and response to treatment 
 Adverse events (SAE=Serious adverse events and ESI=Event of 




Chapter 4 - RESULTS 
4.1 General Demographic Information  
In the present study we have enrolled patients included in the registry with 
complete demographic data up to 28 September 2018: 3843 patients (1903 M e 
1940 F) with complete demographic information have been enrolled from 62 
countries (geographic distribution represented in Figure 1 and Table 2). 
 




































































































































Behcet 214 108 106 190 4 9 2 9 
Blau 49 25 24 24 1 0 6 18 
CAPS 298 146 152 240 13 7 9 29 
CRMO 581 216 365 516 12 16 4 33 
DIRA 3 0 3 2 0 1 0 0 
FMF 1086 565 521 649 8 263 22 144 
MKD 205 93 112 177 12 1 6 9 
NALP12 13 6 7 12 0 0 1 0 
PAPA 42 21 21 31 6 2 2 1 
PFAPA 676 383 293 356 207 92 13 8 
TNF 273 138 135 242 12 3 3 13 
CANDLE 1 0 1 1 0 0 0 0 
Schnitzler 13 6 7 13 0 0 0 0 
Majeed 4 3 1 3 0 0 0 1 
Undefined 368 182 186 301 38 9 5 15 
DADA2 14 10 4 11 0 3 0 0 
SAVI 3 1 2 2 0 0 1 0 
Total 3843 1903 1940 2770 313 406 74 280 
       72% 8% 11% 2% 7% 
Table 2: Geographic distribution of patients enrolled in the study 
2770 (72%) are resident in Western Europe, 313 (8%) in Eastern Europe, 406 
(11%) in Eastern-Southern Mediterranean (Algeria, Egypt, Israel, Lebanon, 
Libya, Morocco, Tunisia, Turkey), 74 (2%) in South America and 280 (7%) in 
other countries (35 Canada, 2 Mexico, 11 Australia, 232 Asia).  
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Compared to the first Eurofever report (Toplak et al, 20125) we have observed 
an increase of enrolled patients number from East-Europe countries (from 6% to 
8%), and also from Asian countries (from 3% to 6%).  
The patients enrolled are affected by the following diseases: 1862 patients 
affected by periodic fevers (1086 with Familial Mediterranean Fever, 298 with 
criopirinopathies, 205 with mevalonate kinase deficiency and 273 with tumor 
necrosis factor receptor associated periodic syndrome. 1852 patients are affected 
by multifactorial autoinflammatory diseases: 676 with periodic fever, aphthous 
stomatitis, pharyngitis, adenitis (PFAPA), 581 with chronic non-bacterial 
osteomyelitis, 214 with Behcet disease, 13 with Schnitzler disease and 368 with 
unknown fever. 129 patients with rare monogenic disease: 49 Blau disease, 42 
PAPA syndrome (pyogenic arthritis, pyoderma gangrenosum, acne), 14 
Deficiency of adenosine deaminase 2 (DADA2), 13 associated periodic fever 
(NALP12), 4 Majeed, 3 deficiency of interleukin-1 receptor antagonist (DIRA), 
3 STING-associated vasculopathy with onset in infancy (SAVI), 1 chronic 
atypical neutrophilic dermatosis with lipodystrophy and elevated temperature 
(CANDLE). 
 
4.2 Onset, Diagnosis and Enrollment 
The median onset age is 4 years (range 1 month – 75 years), the median 
diagnosis age is 8 years (range 1 month – 78 years). 3509 (91%) patients 
presented disease onset during pediatric age (<16 years), 334 (9%) during adult 
age (81 FMF, 31 CAPS, 53 TRAPS, 40 CRMO, 12 Schnitzler syndrome e 90 
unknown fever). (Figure 2) 405 of 3509 (12%) patients with pediatric onset 
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Figure 2: Pediatric/Adult onset 
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Regarding diagnostic delay (defined as time from onset and diagnosis), the 
median value is 5 years; diseases with longer diagnostic delay are: NLRP12 (24 
years, range 4-76), CAPS (15 years, range 0-77), PAPA (14 years, range 2-57), 
TRAPS (12 years, range 0-77). By comparing the mean diagnostic delay from 
1980 to 2018 we have observed a constant reduction of period between AIDs 
onset e diagnosis (Figure 4 and Table 4). 










Behcet 214 4 9 (0-56) 13 (2-57) 
Blau 49 5 4 (0-30) 9 (0-46) 
CAPS 298 15 5 (0-57)  20 (0-77)  
CRMO 581 2 11 (0-62) 13 (1-68) 
DIRA 3 2 2 mth (0-4 mth) 3 (0-7) 
FMF 1086 5 6 (0-66) 11 (0-72) 
MKD 205 10 2 (0-45) 12 (0-51) 
NALP12 13 24 12 (0-29) 36 (4-76) 
PAPA 42 14 6 (0-18) 20 (2-57) 
PFAPA 676 2 3 (0-30) 5 (0-37) 
TNF 273 12 10 (0-63) 22 (0-77) 
CANDLE 1 9 1 10 
Schnitzler 13 3 53 (36-76) 56 (41-78) 
Majeed 4 5 15 (0-55) 20 (1-68) 
Undefined 368 5 12 (0-73) 17 (0-75) 
DADA2 14 8 4 (0-10) 12 (6-18) 
SAVI 3 9 1 (0-4) 10 (1-18) 
Total 3843       


















<1980 6 2,235 14,051 11,816 
1981-1990 19 2,318 9,397 7,079 
1991-2000 170 4,517 11,223 6,706 
2001-2008 1401 5,884 11,586 5,703 
2009-2018 2243 8,031 12,855 4,824 
Table 4: Diagnostic delay (mean) from 1980 to 2018 
 
For 3356 (87%) patients also clinical data from onset to diagnosis, 
collected during the first visit performed at referred Pediatric Rheumatologic 
Center, are available. Since February 2015, longitudinal visits have been inserted 




















Figure 5: Number of patients enrolled in the Eurofever Registry 
 
Regarding periodic fevers, clinical details from onset are available for l’88% 
(951 of 1086) of FMF patients, 94% (279 of 298) of CAPS, 76% (190 of 205) 
of MKD and 94 % (256 of 273) of TRAPS; complete clinical data at baseline are 
available for 76% (98 of 129) patients affected by Rare Monogenic Diseases and 
for 85% of Multifactorial Diseases (1582 of 1852). 
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Figure 6: Age at enrollment time in AIDs 
4.3 Clinical features of Periodic Fevers and PFAPA 
Clinical patterns of periodic fevers are divided into: 
- Continuous 
- Recurrent 
- Continuous-recurrent  
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As shown in Figure 7, most of the patients are affected by recurrent diseases: 
95% of patients with FMF, 49% of CAPS, l’85% of MKD, l’87% of TRAPS and 
91% of PFAPA. 
3% of FMF, 31% of CAPS, 4% of MKD, 6% of TRAPS and 1% of PFAPA 
presents continuous course. A continuous-recurrent form is observed in 2% of 
FMF patients, 20% of CAPS, 8% of MKD, 7% of TRAPS and 8% of PFAPA. 
In order to complete the analysis of clinical features of periodic fevers the 
following data have been collected: 
- Fever episodes duration (Figure 8) 
- Number episodes/year (Figure 9) 
- Pattern of frequency (regular or irregular) (Figure 10) 
- Triggers (Figure 11-13): specific triggers have been found 
respectively in 43% of CAPS patients and 44% of MKD patients. 
Triggers more frequently involved are cold, stress and infections. 
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Figure 9: Number of episodes/year 
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Figure 11: Triggers of episodes 
 
Figure 12: Type of triggers for different diseases (I) 
 
Figure 13: Type of triggers (II) 
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4.4 Genetic analysis 
In the Registry we have identified a total of 1955 patients carriers of 
specific mutations: 1008 FMF, 271 TRAPS, 255 CAPS, 199 MVK, 71 
Undefined Fever, 39 PFAPA, 35 PAPA, 29 Blau, 15 NALP12, 13 DADA2, 5 
Behcet, 1 CANDLE, 1 DIRA, 1 Schnitzer. With the help of the Infever 
registry (http://fmf.igh.cnrs.fr/ISSAID/infevers, a website dedicated to 
mutations responsible for hereditary autoinflammatory diseases, created in 
2002) we have verified the number of validates mutations and their pathogenic 
meaning. For MEFV gene 71% of mutations detected in patients enrolled in the 
Eurofever registry have been validated. 89% of mutations for NLRP3, 90% for 


















FMF MEFV 947 34 24 71% 
FMF TNFRSF1A 7 4 2   
FMF MVK 4 1 1   
FMF NLRP3 1 1 0   
CAPS MEFV 8 1 1   
CAPS MVK 1 1 1   
CAPS NLRP3 207 36 32 89% 
CAPS NLRP12 1 1 1   
CAPS TNFRSF1A 4 1 1   
MVK MEFV 12 5 4   
MVK MVK 171 31 28 90% 
MVK NLRP3 2 2 2   
MVK TNFRSF1A 3 1 1   
TRAPS MEFV 6 3 3   
TRAPS NLRP3 2 2 1   
TRAPS TNFRSF1A 225 40 36 90% 
Table 5: Number of validated mutations for each gene of Periodic Fevers 
 
26% of validated mutations of MEFV gene (Table 6) results pathogenic, 
30% likely pathogenic; 30% of validated mutations of NLRP3 gene results 
pathogenic and 48% likely pathogenic; 53% of validated mutations of MVK 
gene results pathogenic and 33% likely pathogenic. 50% of validated mutations 
















MEFV 27 7 8 2 3 7 
NLRP3 33 11 16 1 0 5 
MVK 30 16 10 2 1 1 
TNFRSF1A 40 20 11 0 4 5 
       
Table 6: Significance of validated mutations of Periodic Fevers gene 
Number of patients carriers of single mutations of different AIDs are 
shown in Figure 14-18. In the Registry we have identified 993 patients carriers 
of MEFV gene mutations: 362 of them present only one mutation: in 224 patients 
this mutation is validated in Infever registry with pathogenic or likely pathogenic 
significance, while in 28 patients the mutation is benign (23 mutations R202Q, 
2 D510D, 1 D102D, 1 G304R and 1 G219G). Instead, 631 patients are carriers 
of two mutations and 423 of them have both mutations with certain or likely 
pathogenic significance, 6 patients have two benign mutations (R202Q) and 16 
patients have one pathogenic and one benign mutations. 
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FMF MEFV 993 38 26 15 5 
FMF TNFRSF1A 7 4 2 0 0 
FMF MVK 4 1 1 0 1 
FMF NLRP3 1 1 1 0 0 
Table 7: Number of patients carriers of MEFV gene mutations 
20 15 2 2
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A744S (p.Ala744Ser) Others mutations
c.625+10A/G () D510D (p.Asp510Asp)
E148Q (p.Glu148Gln) E148V (p.Glu148Val)
F479L (p.Phe479Leu) I591T (p.Ile591Thr)
I641F (p.Ile641Phe) K695R (p.Lys695Arg)
L110P (p.Leu110Pro) M680IGA (p.Met680Ile)
M680IGC (p.Met680Ile) M680L (p.Met680Leu)
M694DEL (p.Met694del) M694I (p.Met694Ile)

























CAPS NLRP3 207 36 32 28 0 
CAPS NLRP12 1 1 0 0 0 
CAPS TNFRSF1A 4 1 1 0 1 
CAPS MEFV 8 1 1 0 0 
CAPS MVK 1 1 1 1 0 
 







































MVK - A334T (p.Ala334Thr) Others
Q703K (p.Gln703Lys) Gene NLRP3 - V198M (p.Val198Met)
A439T (p.Ala439Thr) A439V (p.Ala439Val)
D303N (p.Asp303Asn) E148Q (p.Glu148Gln)
E311K (p.Glu311Lys) I313V (p.Ile313Val)
M662T (p.Met662Thr) Mutation not listed
R260W (p.Arg260Trp) R488K (p.Arg488Lys)
R92Q (p.Arg121Gln) S331R (p.Ser331Arg)
S710C (p.Ser710Cys) T348M (p.Thr348Met)



























MVK MVK 171 31 28 26 2 
MVK NLRP3 2 2 2 0 0 
MVK TNFRSF1A 3 1 1 0 0 
MVK MEFV 12 5 4 2 1 
       
 








3 3 4 3 2 2 2 2 3 2 2 2
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R202Q (p.Arg202Gln) R92Q (p.Arg121Gln)
E148Q (p.Glu148Gln) V377I (p.Val377Ile)
R215Q (p.Arg215Gln) Mutation not listed
S52N (p.Ser52Asn) I268T (p.Ile268Thr)
S272F (p.Ser272Phe) G336S (p.Gly336Ser)
P165L (p.Pro167Leu) L264F (p.Leu264Phe)
T237S (p.Thr237Ser) W188X (p.Trp188X)
H20N (p.His20Asn) G326R (p.Gly326Arg)
L265R (p.Leu265Arg) N205D (p.Asn205Asp)
A148T (p.Ala148Thr) V250I (p.Val250Ile)
Others Mutations MVK I591T (p.Ile591Thr)
M694V (p.Met694Val) Q703K (p.Gln703Lys)



























TRAPS TNFRSF1A 225 40 36 31 3 
TRAPS MEFV 6 3 3 1 0 
TRAPS NLRP3 2 2 1 0 0 
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T50M (p.Thr79Met) R92Q (p.Arg121Gln) C43R (p.Cys72Arg)
D12E (p.Asp41Glu) C52Y (p.Cys81Tyr) E148Q (p.Glu148Gln)
Mutation not listed Others M694V (p.Met694Val)
C55Y (p.Cys84Tyr) E109A (p.Glu138Ala) V95M (p.Val124Met)
N65I (p.Asn94Ile) T37I (p.Thr66Ile) C30R (p.Cys59Arg)
P46L (p.Pro75Leu) C29Y (p.Cys58Tyr) C73W (p.Cys102Trp)
C70R (p.Cys99Arg) D42DEL (p.Asp71del) C33Y (p.Cys62Tyr)
c.472+6C>T () H22R (p.His51Arg) H22Q (p.His51Gln)





Figure 18: Number of patients carriers of rare monogenic mutations 
 
4.5 Treatment and safety  
489 patients have been treated with at least one biologic drug, 1031 with 

























































































































































































































































































































































































































































































Blau's  disease/Juvenile Sarcoidosis
CANDLE syndrome
Deficiency of Adenosine Deaminase 2 (DADA2)
Deficiency of IL-1 receptor antagonist (DIRA)
NALP12-related  disease
PAPA  syndrome (pyoderma gangrenosum, acne, pyogenic arthritis)




Figure 19: Number of patients treated with different drugs (Biologics, 
DMARDS, Steroids, Other drugs) 
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Figure 21: Geographic distribution of patients treated with DMARDS 
 
Biologic Drugs 
22% of patients enrolled in the Eurofever registry has been treated with 
biologic drugs . Among these patients, 26% are Italian. The most frequent 
diseases treated with biologic drugs are (Table 11): CAPS (38%), multifactorial 
diseases (22%, in particular 9% CRMO, 5% Behcet, 5% Undefined Periodic 
Fever, 3% Schnitzler), TRAPS (14%), MKD (11%), rare monogenic (8%: one 
CANDLE patient, 2 DIRA, 2 NALP12, 3 Mayeed, 8 DADA2 and 14 PAPA), 
and FMF (7%). 
The following figures display biologic use distribution in the different countries: 
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  Multifactorial 
Rare 
Monogenic CAPS FMF MKD 
TRAP
S Total 
Armenia             0 
Argentina     4   1   5 
Austria 2 1 1 1 1   6 
Australia     1       1 
Bulgaria             0 
Brasil     1       1 
Canada     1       1 
Switzerland 1   4       5 
Chile       1     1 
Czech Rep.   1 7   1   9 
Germany 18 2 15   1 12 48 
Denmark 9 2 2     1 14 
Ecuador     1       1 
Spain 10 8 3 10 8 3 42 
France 4   44 4 6 3 61 
UK 5 1 49   17 33 105 
Greece       4     4 
Croatia             0 
Hungary 1   1       2 
Israel 1           1 
Italy 57 18 25 7 7 13 127 
Japan     4       4 
Lithuania         1   1 
Latvia             0 
     Netherlands   2 14 2 7   25 
Poland           2 2 
Romania     1       1 
Serbia             0 
Russia     2   1 1 4 
Saudi 
Arabia     1       1 
Slovenia           1 1 
Turckey   5 3 7 1   16 
Total 108 40 184 36 52 69 489 
        
 







Figure 22: Geographic distribution of patients treated with biologics  
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4.6 Eurofever Impact on Scientific Comunity 
During its first 10 years, the Eurofever registry provided 12 papers with 
800 citations. The main new information coming from the registry can be 
summarized as follows: 
 4.6.1 Insights on the clinical presentation, disease course, complications 
and response to treatment for the most common autoinflammatory 
diseases, providing the largest series available in the literature 
 4.6.2.Detailed information on genotype-phenotype correlations in 
hereditary periodic fever syndromes 
 4.6.3 Evaluation of the accuracy of previous diagnostic criteria and 
development of new evidence-based classification criteria 
 4.6.4 Development and validation of novel instruments for the 
management of autoinflammatory diseases in daily practice 
 
4.6.1 Insight on autoinflammatory diseases 
The first analysis of the demographic data coming from the Eurofever 
registry was performed by Toplak et al, in 2012.5 This report gave the first 
overview of the distribution of these rare monogenic conditions based on the 
collection of 1880 patients from 67 centers in 31 countries. Most of the patients 
(74%) lived in western Europe, 16% in the eastern and southern Mediterranean 
region (Turkey, Israel, North Africa). Only 6% of the patients were from eastern 
European countries, highlighting the possibility of a lack of recognition of these 
diseases or lack of resources in some less economically developed countries. The 
study was able to analyze the impact of diagnostic delay in these conditions. The 
median diagnosis delay was 7.3 years (range 0.3-76), with an encouraging 
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reduction in the time to diagnosis in patients born after the identification of the 
first gene associated with autoinflammatory diseases (MEFV for FMF) in 1997.9 
 
Familial Mediterranean fever (FMF) 
The homogeneous collection of pediatric patients with FMF coming from 
different countries and ethnicities enabled for the first time an analysis of the 
impact of ethnic, environmental and genetic factors on the severity of disease 
presentation. For this aim, demographic, genetic and clinical data from pediatric 
patients with FMF enrolled in the Eurofever registry were analyzed. Patients 
were divided into three subgroups: (i) patients living in the eastern 
Mediterranean countries; (ii) patients with an eastern Mediterranean ancestry 
living in western Europe; (iii) Caucasian patients living in western European 
countries.10 
The study was conducted on 346 pediatric patients with FMF from 64 
centers in 28 countries. European patients had a lower frequency of the high 
penetrance M694V mutations and a significant delay of diagnosis (p<0.002). 
The study confirmed in the pediatric setting that patients living in the eastern 
Mediterranean display a more severe disease presentation with a higher 
frequency of fever episodes per year, more frequent arthritis, pericarditis, chest 
pain, abdominal pain and vomiting compared to the other two groups. A 
multivariate analysis was able to confirm that beside the presence of the M694V 
mutation and a positive family history, the country of residence (eastern 
Mediterranean countries) was a variable independently associated with severity 





Cryopyrin-associated periodic syndromes (CAPS) 
Levy et al,11evaluated genetic, demographic and clinical features in 
patients with CAPS from the Eurofever registry. This study was based on the 
collection of 136 CAPS patients enrolled in the registry with a median onset at 
age 9 months, median diagnosis at age 15 years and median follow-up duration 
of 15 years. A heterozygous germline mutation was found in 133 patients, while 
no mutation was identified in 3 patients. Thirty-one different NLRP3 mutations 
were recorded, 7 of which represented 78% of all the patients. More than half of 
the patients (57%) displayed a chronic disease course, while 43% of the patients 
were characterized by recurrent episodes. Fever, cutaneous and musculoskeletal 
involvement were the most prevalent manifestations. Neurological involvement 
was observed in 55 (40%) patients, with severe involvement in 16 (12%). 
Ophthalmological involvement was found in 71% of cases and sensorineural 
hearing loss in 42%. AA amyloidosis was detected in five patients (three 
carrying a R260W mutation, one V198M mutation and one A439 V mutation). 
The authors also analyzed the correlation between genotype and phenotype 
in this cohort. They found that the T348M variant was associated with a more 
severe disease course, characterized by early onset, chronic course and 
neurological involvement. Patients with Q703K polymorphism had a milder 
disease. Results from this study led to a better understanding of risk factors, 
prognosis and genotype-phenotype associations in CAPS patients. These 
findings may have an important impact on therapeutic decisions and on the 






Tumor necrosis factor receptor associated periodic syndrome 
(TRAPS) 
In 2013 Lachmann et al,12 described genetic findings, demographic 
features and clinical presentation of TRAPS in patients from the 
Eurofever/Eurotraps international registry. This study, the largest series of 
TRAPS patients, enrolled 158 patients with a median onset age of 4.3 years; 
median diagnosis age was 25.9 years and median follow-up duration was 15.6 
years. 
The most common TNFRSF1A variant found in 54 patients (34% of cases) 
was R92Q (a low-penetrant variant), followed by T50M (10%). Regarding 
clinical features, the disease course was recurrent in 139 (88%) patients, with 
episode duration of more than 14 days in 25% of cases. About half of the patients 
(43%) displayed attacks of 7-14 days. The most common symptoms besides 
fever were limb pain (85%), abdominal pain (74%), rash (63%) and eye 
manifestations (45%). AA amyloidosis was noted in 16 (10%) patients at a 
median age of 43 years. This large series of patients enabled the description of 
molecular and clinical features of TRAPS syndrome, with emphasis on different 
phenotype among low-penetrant and pathogenic variants. 
 
Mevalonate kinase deficiency (MKD) 
Ter Haar et al,13 evaluated the phenotype, genotype and response to 
treatment of patients with MKD enrolled in the registry. Complete information 
on 114 patients with MKD from 31 centers in 12 countries were available. The 
median onset age was 0.5 years, median age at diagnosis 6.5 years and median 
follow-up period was 11.5 years. The disease was characterized by recurrent 
episodes in 99/114 (87%) patients, with most patients being well between 
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attacks; however, 10-20% displayed constitutional symptoms between fever 
episodes such as malaise (61%), fatigue (61%) and weight loss (1%). 
Gastrointestinal symptoms were observed in almost all the patients (98%).Other 
main features of this series were mucocutaneous involvement in 87% of patients, 
lymphadenopathy in 89% and musculoskeletal symptoms in 78%. 
Regarding neurological involvement, headache was reported as the most 
common symptom (38%).The main complication was AA amyloidosis, which 
developed in 5 (4%) patients, more often in those with p.V377I/p.I268T 
compound heterozygosity. The most common mutation emergent from the 
analysis was p.V377I; 84% of the patients had at least one p.V377I mutation. 
Treatments used included nonsteroidal anti-inflammatory drugs (NSAIDs) 
given to 66 (58%) patients, which relieved symptoms in 48 (73%) of them. 
Corticosteroids given during attacks were completely effective in resolving 
inflammatory episodes in 19/49 (39%) patients with a partial response in 21/49 
(43%). Biologic agents (anakinra, canakinumab and etanercept) were able to 
induce a complete response in many patients. Specifically, anakinra was 
administered to 8 patients only during attacks (5 with complete response, 3 with 
partial response) while 19 patients received anakinra as maintenance treatment; 
13 patients obtained a complete remission, while 3 had a partial response. 
 
Chronic non-bacterial osteomyelitis (CNO) 
Recently, the first report on patients with CNO collected in the Eurofever 
registry has been reported.14 Complete information on 486 patients was 
available, representing the largest series reported to date. The mean age at onset 
was 9.9 years (range 1-17.7 years). Adult onset was observed in 31 (6%) patients. 
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The mean time from disease onset to final diagnosis was 1 year (range 0-15 
years). 
At baseline, all patients displayed musculoskeletal symptoms with 431 
(89%) patients reporting bone pain, 302 (62%) arthralgia, 58 (12%) myalgia, 72 
(15%) monoarthritis, 54 (11%) oligoarthritis and 10 (2%) polyarthritis. Nineteen 
percent of the patients had mucocutaneous manifestations (5% acne, 5% palmo-
plantar pustulosis, 4% psoriasis, 3% papulo-pustular lesions, 2% urticarial rash), 
8% displayed gastrointestinal symptoms. Among imaging techniques, MRI was 
performed at baseline in 426 (88%) patients, revealing a mean number of 4.1 
lesions. Overall, 37% of patients displayed metaphyseal lesions, 23% 
epiphyseal, 15% diaphyseal, 25% pelvic, 23% vertebral, 19% clavicle, 15% 
tarsal, 10% thoracic,  3% carpal and 3% cranial. Bone biopsy was performed in 
281 (58%) patients.  
Three hundred and sixty-one (74%) patients were treated with NSAIDs, 
112 (23%) with corticosteroids, 61 (13%) with bisphosphonates, 58 (12%) with 
methotrexate, 47 (10%) with sulfasalazine, 26 (5%) with anti-TNF and 4 (1%) 
with anakinra, with a variable response to all these treatments. However 
NSAIDs, bisphosphonates and sulfasalazine displayed the highest rate of 
complete or partial response. 
The study showed that CNO often presents during early adolescence and 
the range of clinical manifestations and response to treatment is heterogeneous 
 
4.6.2 Genotype-phenotype correlations 
The large number of polymorphisms and common variants in hereditary 
recurrent fever (HRF) genes makes it difficult to find associations between 
genotype and phenotype. The Infevers database collects all these variants and 
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provides a brief description of clinical manifestations of the first patient reported 
for each mutation. With the aim of improving knowledge of genotype-phenotype 
correlations, Papa et al,15in a recent study, developed an open web-based registry 
of genotype-phenotype associations derived from all the patients with HRF 
enrolled and validated in the Eurofever registry 
 
4.6.3 Development of new classification criteria 
As mentioned previously, one of the main purposes of the Eurofever registry was 
to generate evidence-based diagnostic and classification criteria. Formal 
diagnostic criteria have been developed for some inherited periodic fevers (FMF 
and CAPS), based on the main clinical manifestations associated with the 
specific disease within the context of limited populations. Thus, there is a 
question of their generalization to other populations.16, 17 
Therefore, the large Eurofever registry was used to test the accuracy of different 
diagnostic criteria currently in use for FMF and compared them with the 
performance of previous criteria for the diagnosis of familial Mediterranean 
fever (FMF). 
The performances of the Sohar Tel Hashomer, Livneh Tel-Hashomer, and 
Yalcinkaya FMF criteria were assessed in pediatric patients with FMF compared 
to other periodic fevers, including MKD, TRAPS, CAPS, PFAPA and undefined 
periodic fever from the same registry.18 
The FMF group included 339 patients whereas the control group consisted of 
377 patients (53 TRAPS, 45 MKD, 32 CAPS, 160 PFAPA and 87 undefined 
periodic fevers). Patients with FMF were correctly diagnosed using the 
Yalcinkaya criteria with a sensitivity rate of 87.4% and a specificity rate of 
40.7%. On the other hand, the Sohar Tel Hashomer and Livneh Tel-Hashomer 
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criteria displayed a sensitivity of 45.0 and 77.3%, respectively. Both latter 
criteria displayed a better specificity than the Yalcinkaya criteria: 97.2 and 
41.1% for the Sohar Tel Hashomer and Livneh Tel-Hashomer criteria, 
respectively. The overall accuracy for the Yalcinkaya criteria was 65 and 69.6% 
(using 2 and 3 criteria), respectively. Ethnicity and residence had no effect on 
the performance of the Yalcinkaya criteria. 
Thus, the pediatric Yalcinkaya criteria yielded a better sensitivity than the other 
criteria in this international cohort of patients. However, the specificity was 
lower than the previously suggested adult criteria. 
In 2015 Federici et al,19 developed and validated a new set of clinical criteria for 
the classification of patients affected by the four main autoinflammatory 
recurrent fever syndromes. Patients with HRF (FMF, MKD, TRAPS and CAPS) 
enrolled in the Eurofever Registry until March 2013 were evaluated. Patients 
with PFAPA syndrome were used as negative controls. The ‘gold-standard' for 
diagnosis of the monogenic diseases was based on the presence of a confirmatory 
genetic analysis.20,21Patients with non-confirmatory genetic analysis, such as 
low-penetrance mutations, were excluded from the study. Patients with PFAPA 
were classified according to current diagnostic criteria.22 
Twelve hundred and fifteen patients enrolled in the registry were analyzed: 518 
were selected as the ‘gold standard group’ (291 FMF, 74 MKD, 86 TRAPS and 
67 CAPS) and 119 patients with PFAPA were evaluated as the negative controls. 
The authors randomly divided the ‘gold standard group’ into two subgroups. 
Univariate and multivariate analyses were performed in the first training set 
subgroup (412 patients) to identify clinical variables which strongly correlated 
with each disease. The second validation subgroup (305 patients) was used to 
assess the performance of the 4 scores originated from statistical analysis in an 
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independent group of patients. All criteria displayed a high sensitivity and 
specificity (Table 2). 
This study facilitated the development of a validated evidence-based tool that 
may be useful either as an indication for performing genetic testing or for clinical 
classification of patients with suspected autoinflammatory periodic fevers. 
 
4.6.4 Validation of disease activity and damage scores 
As previously stated, the main outcome measure in therapeutic trials is the 
disease activity. However, validated indices of disease activity were lacking 
before the creation of the registry. Development and validation of these activity 
parameters represented another aim of the Eurofever project. 
The first index of activity (Autoinflammatory Diseases Activity Index, AIDAI) 
was proposed in 2013 for patients affected by the four major HRF syndromes: 
FMF, MKD, TRAPS and CAPS .23 
This study was initiated in November 2010 by an international collaboration of 
eight centers belonging to the PRINTO/Eurofever network. They established the 
content of a disease activity tool for HRFs and started with the enrollment of 
consecutive patients attending participating centers. Each patient had to 
complete a 1-month prospective diary before a scheduled clinical appointment 
during which the physician assessed the disease activity by a questionnaire. Data 
coming from the various centers were centrally collected in the Eurofever 
database and then eight international experts in autoinflammatory diseases 
evaluated the patients' disease activity by a blinded web evaluation. The second 
step of score validation was a consensus conference where the experts evaluated 
the level of disease activity. The last step of the study was the calculation of the 
score to discriminate active from inactive disease by statistical analysis. 
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One hundred six patients were enrolled (42 FMF, 39 CAPS, 14 TRAPS and 11 
MKD). During the second step of the validation process, consensus was achieved 
for 98/106 (92%) cases (39 FMF, 35 CAPS, 14 TRAPS and 10 MKD); 26 
patients were declared to have inactive disease and 72 had active disease, with 
different grades of activity (low-mild-severe). Statistical analysis performed 
with receiver operating characteristic (ROC) curve revealed that an AIDAI cut-
off score ≥9 discriminated active from inactive disease with the best accuracy 
(sensitivity of 89% and specificity of 92%). 
After this first study, a damage index score (Autoinflammatory Disease 
Damage Index, ADDI) was developed in 2016 by Ter Haar at al,24 for FMF, 
CAPS, TRAPS and MKD . The top 40 enrollers of patients in the Eurofever 
registry and 9 experts from the Americas participated in multiple rounds of 
online surveys to select items and definitions of damage. Also 22 patients or 
parents of patients were invited to participate in an online survey. Authors used 
the 1000minds software to assess the scoring system of ADDI with the correct 
weight to each damage item. The online surveys were completed by >80% of 
experts, who suggested 16 new damage items. The next step of the index 
assessment was a consensus meeting, which was attended by 31 experts. During 
this meeting, items that didn’t reach consensus in the online survey were 
discussed. At the end of this process, the preliminary ADDI score contained 18 
items, classified in the following categories: reproductive, renal/amyloidosis, 
developmental, serosal, neurological, ears, ocular and musculoskeletal damage, 
each with a different weight. The highest weight was attributed to renal and 
neurological categories. Authors highlighted the strength of this index score, due 
to the number of experts that attended the survey and to the involvement of 
patients or parent of patients. 
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Chapter 5 - DISCUSSION 
In the present study we purpose to highlight the support of Eurofever 
project for identification and characterization of AIDs. The main features of a 
successful international registry are a widespread involvement of international 
Centers and a continuous updating from enrolling centers. The first demographic 
study of Toplak et al5(2012) was based on analysis of the first 1880 enrolled 
patients, coming from 31 Countries. The present study analyzes the enrollment 
during the first ten years of the registry and it represents a great opportunity for 
knowledge of these rare diseases, with the collection of data from almost 4000 
patients all over the world. In the last years we have observe an encouraging 
increase of involved Countries, with a greater number  of patients coming from 
geographic area, poorly represented  in the first epidemiologic study of Toplak 
et al. Interestingly, we have observed an increase of 2 % of patients enrolled in 
Eastern-Europe and of 3 % in Asian Countries. These findings suggest a 
progressive improvement of knowledge of these rare disorders also in emerging 
Countries and with limited access to genetic analysis. The analysis of Eurofever 
data confirm that most of patients affected by AIDs present a disease onset 
during pediatric age, underlining the importance of an early diagnosis. A relevant 
part of patients (405 patients, 12% of total population) presented a pediatric 
onset, but received diagnosis only in adult age. Diagnostic delay represents a 
major issues for rare diseases. Complications of non-treated disease 
(amyloidosis, kidney insufficiency, earing-loss, mental delay etc) represent an 
increased risk of morbility and long term irreversible damage. Eurofever data 
analysis has confirmed an improvement of diagnostic ability during the last 
years, with a reduction of mean diagnostic delay. 
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Besides these data, the registry highlighted as almost 10% (334) of enrolled 
patients presented disease onset during adult age; these patients are not only 
patients affected by multifactorial disorders, but also affected by monogenic 
diseases (like CAPS and TRAPS). In these last cases the mutations detected are 
polymorphism or variants with low penetrance (compared to the total of adult 
patients with validate mutations, 16% of CAPS and 23% of TRAPS present 
pathogenic variants of likely pathogenic). Regarding the pattern of frequency of 
diseases, for monogenic periodic fevers (TRAPS, FMF, CAPS, MKD) a variable 
percentage of patients presents a chronic course (typically in severe forms of 
CAPS and MKD). To date, in the registry detailed data about clinical 
manifestations are available for 88% of patients.  
Finally, the Eurofever registry allowed the analysis of global therapeutic 
approach for autoinflammatory diseases. The use of NSAIDs, steroid on demand 
and Colchicine still represents the most used approach. The use of biologics 
represents a new opportunity for the treatment of AIDs; data coming from 
Eurofever highlight how biologics are mostly used in developed countries, while 
their use in emerging countries is still limited. In the present study, we have 
evaluated the impact of the Registry on Scientific Community; during its first 10 
years, the Eurofever registry provided 12 papers with 800 citations. Detailed 
analysis of clinical features collected in Eurofever database allowed to perform 
studies with large cohort of patients10,11,12,13,14,to purpose new classification 
criteria19, to validate damage and activity score and to evaluated 
genotype/phenotype correlation15. At the beginning of the project, the Eurofever 
database collected exclusively data from disease onset to diagnosis, based on 
retrospective information collected during the first visit at referred Center. 
During the following years, it was clear the need to establish a register able to 
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observe the long-term evolution of diseases, the compliance and efficacy of 
different therapeutic approach. In February 2015 we started the longitudinal 
collection of data, with a particular focus on treatment and safety. To date, 
longitudinal data are available for about 12% of enrolled patients. The 
enrollment of patients in Eurofever Registry is still ongoing. The creation of a 
large cohort of follow-up data, with focus on treatment and safety, will allow a 
better knowledge on natural history of these rare diseases, improving the 
management of patients affected by these conditions. In conclusion, during this 
first 10 years, the international effort to build a common registry on 
autoinflammatory diseases led to a considerable accumulation of new 
information, concerning the modality of presentation, disease course, genotype-
phenotype correlations and response to treatment in rare inflammatory 
conditions. New tools for every-day practice have been also developed with an 
evidence-based approach coming from real patients enrolled in the registry. 
Studies on other rare and newly recognized conditions (such as DADA2 and 
interferonopathies) are currently ongoing. Long-term studies will help 
understand the efficacy and safety of different treatments used in these rare 
conditions. 
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